Small-molecule inhibitors targeting the NLRP3 inflammasome: advances since mid-2023 and future perspectives

targeted protein degradation (TPD) and the discovery of natural product-derived inhibitors, are also highlighted as growing areas of interest. By providing new perspectives on lead identification, structure-activity relationships (SARs) optimization, mechanistic studies, and clinical translation, this review aims to facilitate the rational design and development of next-generation NLRP3.